Global Genomic Cancer Testing Market Growth (Status and Outlook) 2026-2032
The global Genomic Cancer Testing market size is predicted to grow from US$ 16455 million in 2025 to US$ 30739 million in 2032; it is expected to grow at a CAGR of 9.4% from 2026 to 2032.
Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.
Gross Profit Margin Levels
Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not ?how much money is made per sample tested,? but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.
Industry Drivers
The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an ?optional item? into ?part of the standard process??the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.
LPI (LP Information)' newest research report, the ?Genomic Cancer Testing Industry Forecast? looks at past sales and reviews total world Genomic Cancer Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Genomic Cancer Testing sales for 2026 through 2032. With Genomic Cancer Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genomic Cancer Testing industry.
This Insight Report provides a comprehensive analysis of the global Genomic Cancer Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Genomic Cancer Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Genomic Cancer Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genomic Cancer Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genomic Cancer Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Genomic Cancer Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
Genomic Cancer Testing refers to a class of molecular diagnostic technologies and services that analyze DNA, RNA and other molecular-level genetic information in a patient's tumor tissue or body fluids (such as circulating tumor DNA, ctDNA in blood) to identify gene mutations, copy number variations, gene fusions, abnormal expression or epigenetic changes related to the occurrence, development, subtype, treatment response and recurrence of cancer.
Gross Profit Margin Levels
Genomic cancer testing is an industry with high technological barriers, high data interpretation value, but also highly dependent on laboratory automation, sample size, and payment coverage. Overall, the industry's gross profit margin is typically significantly higher than that of routine testing projects. Based on comparable listed companies and industry experience, the gross profit margin for tumor gene testing business at comprehensive laboratory companies is commonly in the 50%-60% range, while leading pure molecular diagnostics/liquid biopsy/high-end CGP companies can typically reach 60%-75%. Among these, product lines with high automation, strong data reuse capabilities, high report added value, and good medical/commercial insurance coverage usually have even higher gross profit margins. Conversely, if a company primarily focuses on customized projects, low-throughput orders, complex manual interpretation, or regional sample delivery services, the gross profit margin will be diluted by channel costs, labor costs, and logistics costs. Therefore, the core of this industry is not ?how much money is made per sample tested,? but rather the quality of profitability is determined by platform-based testing capabilities, database capabilities, clinical evidence capabilities, and payment capabilities. The average gross profit margin level in this industry can generally be understood as higher than traditional pathology testing, lower than pure software SaaS, but significantly higher than most routine outsourced testing projects.
Industry Drivers
The growth of the genomic cancer testing industry is primarily driven by the continued rise in the cancer burden. WHO/IARC data shows that nearly 20 million new cancer cases were diagnosed globally in 2022, and this number is projected to reach 35 million by 2050. This directly increases the long-term demand for early screening, subtyping, targeted therapy selection, efficacy evaluation, and recurrence monitoring. Secondly, the increasing penetration rate of precision medicine is the most crucial catalyst for the industry. The NCI has explicitly incorporated biomarker testing into its treatment decision-making process, and the increasing number of FDA-approved companion diagnostics means that more and more anti-tumor drugs will rely on molecular testing for patient screening. Thirdly, improvements in the payment and regulatory environment are transforming tumor gene testing from an ?optional item? into ?part of the standard process??the extension of CMS's NGS coverage policy and the clear payment pricing for high-value CGP projects are strengthening the industry's business loop. Meanwhile, liquid biopsy, methylation detection, MRD, AI interpretation, and multi-omics joint analysis are continuously improving detection sensitivity, lowering sampling thresholds, and extending testing scenarios from single-diagnosis to full-course disease management. Finally, pharmaceutical companies' demand for companion diagnostics, biomarker discovery, patient stratification, and real-world evidence is also driving the industry to upgrade from a single testing business to a composite market encompassing clinical services, drug development, and data asset operation.
LPI (LP Information)' newest research report, the ?Genomic Cancer Testing Industry Forecast? looks at past sales and reviews total world Genomic Cancer Testing sales in 2025, providing a comprehensive analysis by region and market sector of projected Genomic Cancer Testing sales for 2026 through 2032. With Genomic Cancer Testing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Genomic Cancer Testing industry.
This Insight Report provides a comprehensive analysis of the global Genomic Cancer Testing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Genomic Cancer Testing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Genomic Cancer Testing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Genomic Cancer Testing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Genomic Cancer Testing.
This report presents a comprehensive overview, market shares, and growth opportunities of Genomic Cancer Testing market by product type, application, key players and key regions and countries.
Segmentation by Type:
- Next-Generation Sequencing (NGS) Testing Products
- Digital PCR (dPCR) Testing Products
- Others
- Tissue Sample Testing
- Blood Biopsy
- Others
- Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
- Genome Testing Products Specifically For Single Cancer Types
- Others
- Healthcare Institutions
- Biopharmaceuticals and Pharmaceuticals
- Independent Medical Laboratories
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Guardant Health (USA)
- Foundation Medicine (USA)
- Caris Life Sciences (USA)
- Tempus AI (USA)
- NeoGenomics (USA)
- Natera (USA)
- OncoDNA (Belgium)
- Agendia (Netherlands)
- Eurofins Clinical Diagnostics (Luxembourg)
- Unilabs Genetics (Switzerland)
- Nucleix (Israel)
- Genetron Health (China)
- Macrogen (South Korea)
- Geneseeq (China)
- 3DMed (China)
- BGI Genomics (China)
- Canhelp Genomics (China)
- Lucence (Singapore)
- MiRXES (Singapore)
- ACT Genomics (Taiwan)
- MedGenome (India)
- Strand Life Sciences (India)
- Sonic Genetics (Australia)
- NeoGenomics (USA)
- Labcorp Oncology (USA)
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Genomic Cancer Testing Market Size (2021-2032)
2.1.2 Genomic Cancer Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Genomic Cancer Testing by Country/Region (2021, 2025 & 2032)
2.2 Genomic Cancer Testing Segment by Type
2.2.1 Next-Generation Sequencing (NGS) Testing Products
2.2.2 Digital PCR (dPCR) Testing Products
2.2.3 Others
2.2.4 Genomic Cancer Testing Market Size by Type
2.2.4.1 Genomic Cancer Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
2.3 Genomic Cancer Testing Segment by Sample Type
2.3.1 Tissue Sample Testing
2.3.2 Blood Biopsy
2.3.3 Others
2.3.4 Genomic Cancer Testing Market Size by Sample Type
2.3.4.1 Genomic Cancer Testing Market Size CAGR by Sample Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2026)
2.4 Genomic Cancer Testing Segment by Cancer Type Coverage
2.4.1 Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
2.4.2 Genome Testing Products Specifically For Single Cancer Types
2.4.3 Others
2.4.4 Genomic Cancer Testing Market Size by Cancer Type Coverage
2.4.4.1 Genomic Cancer Testing Market Size CAGR by Cancer Type Coverage (2021 VS 2025 VS 2032)
2.4.4.2 Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2026)
2.5 Genomic Cancer Testing Segment by Application
2.5.1 Healthcare Institutions
2.5.2 Biopharmaceuticals and Pharmaceuticals
2.5.3 Independent Medical Laboratories
2.5.4 Others
2.5.5 Genomic Cancer Testing Market Size by Application
2.5.5.1 Genomic Cancer Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
3 GENOMIC CANCER TESTING MARKET SIZE BY PLAYER
3.1 Genomic Cancer Testing Market Size Market Share by Player
3.1.1 Global Genomic Cancer Testing Revenue by Player (2021-2026)
3.1.2 Global Genomic Cancer Testing Revenue Market Share by Player (2021-2026)
3.2 Global Genomic Cancer Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENOMIC CANCER TESTING BY REGION
4.1 Genomic Cancer Testing Market Size by Region (2021-2026)
4.2 Global Genomic Cancer Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Genomic Cancer Testing Market Size Growth (2021-2026)
4.4 APAC Genomic Cancer Testing Market Size Growth (2021-2026)
4.5 Europe Genomic Cancer Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Genomic Cancer Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Genomic Cancer Testing Market Size by Country (2021-2026)
5.2 Americas Genomic Cancer Testing Market Size by Type (2021-2026)
5.3 Americas Genomic Cancer Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genomic Cancer Testing Market Size by Region (2021-2026)
6.2 APAC Genomic Cancer Testing Market Size by Type (2021-2026)
6.3 APAC Genomic Cancer Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Genomic Cancer Testing Market Size by Country (2021-2026)
7.2 Europe Genomic Cancer Testing Market Size by Type (2021-2026)
7.3 Europe Genomic Cancer Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Genomic Cancer Testing by Region (2021-2026)
8.2 Middle East & Africa Genomic Cancer Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Genomic Cancer Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENOMIC CANCER TESTING MARKET FORECAST
10.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)
10.1.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)
10.1.2 Americas Genomic Cancer Testing Forecast
10.1.3 APAC Genomic Cancer Testing Forecast
10.1.4 Europe Genomic Cancer Testing Forecast
10.1.5 Middle East & Africa Genomic Cancer Testing Forecast
10.2 Americas Genomic Cancer Testing Forecast by Country (2027-2032)
10.2.1 United States Market Genomic Cancer Testing Forecast
10.2.2 Canada Market Genomic Cancer Testing Forecast
10.2.3 Mexico Market Genomic Cancer Testing Forecast
10.2.4 Brazil Market Genomic Cancer Testing Forecast
10.3 APAC Genomic Cancer Testing Forecast by Region (2027-2032)
10.3.1 China Genomic Cancer Testing Market Forecast
10.3.2 Japan Market Genomic Cancer Testing Forecast
10.3.3 Korea Market Genomic Cancer Testing Forecast
10.3.4 Southeast Asia Market Genomic Cancer Testing Forecast
10.3.5 India Market Genomic Cancer Testing Forecast
10.3.6 Australia Market Genomic Cancer Testing Forecast
10.4 Europe Genomic Cancer Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Genomic Cancer Testing Forecast
10.4.2 France Market Genomic Cancer Testing Forecast
10.4.3 UK Market Genomic Cancer Testing Forecast
10.4.4 Italy Market Genomic Cancer Testing Forecast
10.4.5 Russia Market Genomic Cancer Testing Forecast
10.5 Middle East & Africa Genomic Cancer Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Genomic Cancer Testing Forecast
10.5.2 South Africa Market Genomic Cancer Testing Forecast
10.5.3 Israel Market Genomic Cancer Testing Forecast
10.5.4 Turkey Market Genomic Cancer Testing Forecast
10.6 Global Genomic Cancer Testing Forecast by Type (2027-2032)
10.7 Global Genomic Cancer Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Genomic Cancer Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Guardant Health (USA)
11.1.1 Guardant Health (USA) Company Information
11.1.2 Guardant Health (USA) Genomic Cancer Testing Product Offered
11.1.3 Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Guardant Health (USA) Main Business Overview
11.1.5 Guardant Health (USA) Latest Developments
11.2 Foundation Medicine (USA)
11.2.1 Foundation Medicine (USA) Company Information
11.2.2 Foundation Medicine (USA) Genomic Cancer Testing Product Offered
11.2.3 Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Foundation Medicine (USA) Main Business Overview
11.2.5 Foundation Medicine (USA) Latest Developments
11.3 Caris Life Sciences (USA)
11.3.1 Caris Life Sciences (USA) Company Information
11.3.2 Caris Life Sciences (USA) Genomic Cancer Testing Product Offered
11.3.3 Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Caris Life Sciences (USA) Main Business Overview
11.3.5 Caris Life Sciences (USA) Latest Developments
11.4 Tempus AI (USA)
11.4.1 Tempus AI (USA) Company Information
11.4.2 Tempus AI (USA) Genomic Cancer Testing Product Offered
11.4.3 Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Tempus AI (USA) Main Business Overview
11.4.5 Tempus AI (USA) Latest Developments
11.5 NeoGenomics (USA)
11.5.1 NeoGenomics (USA) Company Information
11.5.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered
11.5.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 NeoGenomics (USA) Main Business Overview
11.5.5 NeoGenomics (USA) Latest Developments
11.6 Natera (USA)
11.6.1 Natera (USA) Company Information
11.6.2 Natera (USA) Genomic Cancer Testing Product Offered
11.6.3 Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Natera (USA) Main Business Overview
11.6.5 Natera (USA) Latest Developments
11.7 OncoDNA (Belgium)
11.7.1 OncoDNA (Belgium) Company Information
11.7.2 OncoDNA (Belgium) Genomic Cancer Testing Product Offered
11.7.3 OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 OncoDNA (Belgium) Main Business Overview
11.7.5 OncoDNA (Belgium) Latest Developments
11.8 Agendia (Netherlands)
11.8.1 Agendia (Netherlands) Company Information
11.8.2 Agendia (Netherlands) Genomic Cancer Testing Product Offered
11.8.3 Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Agendia (Netherlands) Main Business Overview
11.8.5 Agendia (Netherlands) Latest Developments
11.9 Eurofins Clinical Diagnostics (Luxembourg)
11.9.1 Eurofins Clinical Diagnostics (Luxembourg) Company Information
11.9.2 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product Offered
11.9.3 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Eurofins Clinical Diagnostics (Luxembourg) Main Business Overview
11.9.5 Eurofins Clinical Diagnostics (Luxembourg) Latest Developments
11.10 Unilabs Genetics (Switzerland)
11.10.1 Unilabs Genetics (Switzerland) Company Information
11.10.2 Unilabs Genetics (Switzerland) Genomic Cancer Testing Product Offered
11.10.3 Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Unilabs Genetics (Switzerland) Main Business Overview
11.10.5 Unilabs Genetics (Switzerland) Latest Developments
11.11 Nucleix (Israel)
11.11.1 Nucleix (Israel) Company Information
11.11.2 Nucleix (Israel) Genomic Cancer Testing Product Offered
11.11.3 Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Nucleix (Israel) Main Business Overview
11.11.5 Nucleix (Israel) Latest Developments
11.12 Genetron Health (China)
11.12.1 Genetron Health (China) Company Information
11.12.2 Genetron Health (China) Genomic Cancer Testing Product Offered
11.12.3 Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Genetron Health (China) Main Business Overview
11.12.5 Genetron Health (China) Latest Developments
11.13 Macrogen (South Korea)
11.13.1 Macrogen (South Korea) Company Information
11.13.2 Macrogen (South Korea) Genomic Cancer Testing Product Offered
11.13.3 Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Macrogen (South Korea) Main Business Overview
11.13.5 Macrogen (South Korea) Latest Developments
11.14 Geneseeq (China)
11.14.1 Geneseeq (China) Company Information
11.14.2 Geneseeq (China) Genomic Cancer Testing Product Offered
11.14.3 Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Geneseeq (China) Main Business Overview
11.14.5 Geneseeq (China) Latest Developments
11.15 3DMed (China)
11.15.1 3DMed (China) Company Information
11.15.2 3DMed (China) Genomic Cancer Testing Product Offered
11.15.3 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 3DMed (China) Main Business Overview
11.15.5 3DMed (China) Latest Developments
11.16 BGI Genomics (China)
11.16.1 BGI Genomics (China) Company Information
11.16.2 BGI Genomics (China) Genomic Cancer Testing Product Offered
11.16.3 BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 BGI Genomics (China) Main Business Overview
11.16.5 BGI Genomics (China) Latest Developments
11.17 Canhelp Genomics (China)
11.17.1 Canhelp Genomics (China) Company Information
11.17.2 Canhelp Genomics (China) Genomic Cancer Testing Product Offered
11.17.3 Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Canhelp Genomics (China) Main Business Overview
11.17.5 Canhelp Genomics (China) Latest Developments
11.18 Lucence (Singapore)
11.18.1 Lucence (Singapore) Company Information
11.18.2 Lucence (Singapore) Genomic Cancer Testing Product Offered
11.18.3 Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Lucence (Singapore) Main Business Overview
11.18.5 Lucence (Singapore) Latest Developments
11.19 MiRXES (Singapore)
11.19.1 MiRXES (Singapore) Company Information
11.19.2 MiRXES (Singapore) Genomic Cancer Testing Product Offered
11.19.3 MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 MiRXES (Singapore) Main Business Overview
11.19.5 MiRXES (Singapore) Latest Developments
11.20 ACT Genomics (Taiwan)
11.20.1 ACT Genomics (Taiwan) Company Information
11.20.2 ACT Genomics (Taiwan) Genomic Cancer Testing Product Offered
11.20.3 ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 ACT Genomics (Taiwan) Main Business Overview
11.20.5 ACT Genomics (Taiwan) Latest Developments
11.21 MedGenome (India)
11.21.1 MedGenome (India) Company Information
11.21.2 MedGenome (India) Genomic Cancer Testing Product Offered
11.21.3 MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 MedGenome (India) Main Business Overview
11.21.5 MedGenome (India) Latest Developments
11.22 Strand Life Sciences (India)
11.22.1 Strand Life Sciences (India) Company Information
11.22.2 Strand Life Sciences (India) Genomic Cancer Testing Product Offered
11.22.3 Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Strand Life Sciences (India) Main Business Overview
11.22.5 Strand Life Sciences (India) Latest Developments
11.23 Sonic Genetics (Australia)
11.23.1 Sonic Genetics (Australia) Company Information
11.23.2 Sonic Genetics (Australia) Genomic Cancer Testing Product Offered
11.23.3 Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Sonic Genetics (Australia) Main Business Overview
11.23.5 Sonic Genetics (Australia) Latest Developments
11.24 NeoGenomics (USA)
11.24.1 NeoGenomics (USA) Company Information
11.24.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered
11.24.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 NeoGenomics (USA) Main Business Overview
11.24.5 NeoGenomics (USA) Latest Developments
11.25 Labcorp Oncology (USA)
11.25.1 Labcorp Oncology (USA) Company Information
11.25.2 Labcorp Oncology (USA) Genomic Cancer Testing Product Offered
11.25.3 Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Labcorp Oncology (USA) Main Business Overview
11.25.5 Labcorp Oncology (USA) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Genomic Cancer Testing Market Size (2021-2032)
2.1.2 Genomic Cancer Testing Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Genomic Cancer Testing by Country/Region (2021, 2025 & 2032)
2.2 Genomic Cancer Testing Segment by Type
2.2.1 Next-Generation Sequencing (NGS) Testing Products
2.2.2 Digital PCR (dPCR) Testing Products
2.2.3 Others
2.2.4 Genomic Cancer Testing Market Size by Type
2.2.4.1 Genomic Cancer Testing Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.4.2 Global Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
2.3 Genomic Cancer Testing Segment by Sample Type
2.3.1 Tissue Sample Testing
2.3.2 Blood Biopsy
2.3.3 Others
2.3.4 Genomic Cancer Testing Market Size by Sample Type
2.3.4.1 Genomic Cancer Testing Market Size CAGR by Sample Type (2021 VS 2025 VS 2032)
2.3.4.2 Global Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2026)
2.4 Genomic Cancer Testing Segment by Cancer Type Coverage
2.4.1 Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
2.4.2 Genome Testing Products Specifically For Single Cancer Types
2.4.3 Others
2.4.4 Genomic Cancer Testing Market Size by Cancer Type Coverage
2.4.4.1 Genomic Cancer Testing Market Size CAGR by Cancer Type Coverage (2021 VS 2025 VS 2032)
2.4.4.2 Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2026)
2.5 Genomic Cancer Testing Segment by Application
2.5.1 Healthcare Institutions
2.5.2 Biopharmaceuticals and Pharmaceuticals
2.5.3 Independent Medical Laboratories
2.5.4 Others
2.5.5 Genomic Cancer Testing Market Size by Application
2.5.5.1 Genomic Cancer Testing Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.5.2 Global Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
3 GENOMIC CANCER TESTING MARKET SIZE BY PLAYER
3.1 Genomic Cancer Testing Market Size Market Share by Player
3.1.1 Global Genomic Cancer Testing Revenue by Player (2021-2026)
3.1.2 Global Genomic Cancer Testing Revenue Market Share by Player (2021-2026)
3.2 Global Genomic Cancer Testing Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 GENOMIC CANCER TESTING BY REGION
4.1 Genomic Cancer Testing Market Size by Region (2021-2026)
4.2 Global Genomic Cancer Testing Annual Revenue by Country/Region (2021-2026)
4.3 Americas Genomic Cancer Testing Market Size Growth (2021-2026)
4.4 APAC Genomic Cancer Testing Market Size Growth (2021-2026)
4.5 Europe Genomic Cancer Testing Market Size Growth (2021-2026)
4.6 Middle East & Africa Genomic Cancer Testing Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Genomic Cancer Testing Market Size by Country (2021-2026)
5.2 Americas Genomic Cancer Testing Market Size by Type (2021-2026)
5.3 Americas Genomic Cancer Testing Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Genomic Cancer Testing Market Size by Region (2021-2026)
6.2 APAC Genomic Cancer Testing Market Size by Type (2021-2026)
6.3 APAC Genomic Cancer Testing Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Genomic Cancer Testing Market Size by Country (2021-2026)
7.2 Europe Genomic Cancer Testing Market Size by Type (2021-2026)
7.3 Europe Genomic Cancer Testing Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Genomic Cancer Testing by Region (2021-2026)
8.2 Middle East & Africa Genomic Cancer Testing Market Size by Type (2021-2026)
8.3 Middle East & Africa Genomic Cancer Testing Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL GENOMIC CANCER TESTING MARKET FORECAST
10.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)
10.1.1 Global Genomic Cancer Testing Forecast by Region (2027-2032)
10.1.2 Americas Genomic Cancer Testing Forecast
10.1.3 APAC Genomic Cancer Testing Forecast
10.1.4 Europe Genomic Cancer Testing Forecast
10.1.5 Middle East & Africa Genomic Cancer Testing Forecast
10.2 Americas Genomic Cancer Testing Forecast by Country (2027-2032)
10.2.1 United States Market Genomic Cancer Testing Forecast
10.2.2 Canada Market Genomic Cancer Testing Forecast
10.2.3 Mexico Market Genomic Cancer Testing Forecast
10.2.4 Brazil Market Genomic Cancer Testing Forecast
10.3 APAC Genomic Cancer Testing Forecast by Region (2027-2032)
10.3.1 China Genomic Cancer Testing Market Forecast
10.3.2 Japan Market Genomic Cancer Testing Forecast
10.3.3 Korea Market Genomic Cancer Testing Forecast
10.3.4 Southeast Asia Market Genomic Cancer Testing Forecast
10.3.5 India Market Genomic Cancer Testing Forecast
10.3.6 Australia Market Genomic Cancer Testing Forecast
10.4 Europe Genomic Cancer Testing Forecast by Country (2027-2032)
10.4.1 Germany Market Genomic Cancer Testing Forecast
10.4.2 France Market Genomic Cancer Testing Forecast
10.4.3 UK Market Genomic Cancer Testing Forecast
10.4.4 Italy Market Genomic Cancer Testing Forecast
10.4.5 Russia Market Genomic Cancer Testing Forecast
10.5 Middle East & Africa Genomic Cancer Testing Forecast by Region (2027-2032)
10.5.1 Egypt Market Genomic Cancer Testing Forecast
10.5.2 South Africa Market Genomic Cancer Testing Forecast
10.5.3 Israel Market Genomic Cancer Testing Forecast
10.5.4 Turkey Market Genomic Cancer Testing Forecast
10.6 Global Genomic Cancer Testing Forecast by Type (2027-2032)
10.7 Global Genomic Cancer Testing Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Genomic Cancer Testing Forecast
11 KEY PLAYERS ANALYSIS
11.1 Guardant Health (USA)
11.1.1 Guardant Health (USA) Company Information
11.1.2 Guardant Health (USA) Genomic Cancer Testing Product Offered
11.1.3 Guardant Health (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Guardant Health (USA) Main Business Overview
11.1.5 Guardant Health (USA) Latest Developments
11.2 Foundation Medicine (USA)
11.2.1 Foundation Medicine (USA) Company Information
11.2.2 Foundation Medicine (USA) Genomic Cancer Testing Product Offered
11.2.3 Foundation Medicine (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Foundation Medicine (USA) Main Business Overview
11.2.5 Foundation Medicine (USA) Latest Developments
11.3 Caris Life Sciences (USA)
11.3.1 Caris Life Sciences (USA) Company Information
11.3.2 Caris Life Sciences (USA) Genomic Cancer Testing Product Offered
11.3.3 Caris Life Sciences (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Caris Life Sciences (USA) Main Business Overview
11.3.5 Caris Life Sciences (USA) Latest Developments
11.4 Tempus AI (USA)
11.4.1 Tempus AI (USA) Company Information
11.4.2 Tempus AI (USA) Genomic Cancer Testing Product Offered
11.4.3 Tempus AI (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Tempus AI (USA) Main Business Overview
11.4.5 Tempus AI (USA) Latest Developments
11.5 NeoGenomics (USA)
11.5.1 NeoGenomics (USA) Company Information
11.5.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered
11.5.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 NeoGenomics (USA) Main Business Overview
11.5.5 NeoGenomics (USA) Latest Developments
11.6 Natera (USA)
11.6.1 Natera (USA) Company Information
11.6.2 Natera (USA) Genomic Cancer Testing Product Offered
11.6.3 Natera (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Natera (USA) Main Business Overview
11.6.5 Natera (USA) Latest Developments
11.7 OncoDNA (Belgium)
11.7.1 OncoDNA (Belgium) Company Information
11.7.2 OncoDNA (Belgium) Genomic Cancer Testing Product Offered
11.7.3 OncoDNA (Belgium) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 OncoDNA (Belgium) Main Business Overview
11.7.5 OncoDNA (Belgium) Latest Developments
11.8 Agendia (Netherlands)
11.8.1 Agendia (Netherlands) Company Information
11.8.2 Agendia (Netherlands) Genomic Cancer Testing Product Offered
11.8.3 Agendia (Netherlands) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Agendia (Netherlands) Main Business Overview
11.8.5 Agendia (Netherlands) Latest Developments
11.9 Eurofins Clinical Diagnostics (Luxembourg)
11.9.1 Eurofins Clinical Diagnostics (Luxembourg) Company Information
11.9.2 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product Offered
11.9.3 Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Eurofins Clinical Diagnostics (Luxembourg) Main Business Overview
11.9.5 Eurofins Clinical Diagnostics (Luxembourg) Latest Developments
11.10 Unilabs Genetics (Switzerland)
11.10.1 Unilabs Genetics (Switzerland) Company Information
11.10.2 Unilabs Genetics (Switzerland) Genomic Cancer Testing Product Offered
11.10.3 Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Unilabs Genetics (Switzerland) Main Business Overview
11.10.5 Unilabs Genetics (Switzerland) Latest Developments
11.11 Nucleix (Israel)
11.11.1 Nucleix (Israel) Company Information
11.11.2 Nucleix (Israel) Genomic Cancer Testing Product Offered
11.11.3 Nucleix (Israel) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Nucleix (Israel) Main Business Overview
11.11.5 Nucleix (Israel) Latest Developments
11.12 Genetron Health (China)
11.12.1 Genetron Health (China) Company Information
11.12.2 Genetron Health (China) Genomic Cancer Testing Product Offered
11.12.3 Genetron Health (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 Genetron Health (China) Main Business Overview
11.12.5 Genetron Health (China) Latest Developments
11.13 Macrogen (South Korea)
11.13.1 Macrogen (South Korea) Company Information
11.13.2 Macrogen (South Korea) Genomic Cancer Testing Product Offered
11.13.3 Macrogen (South Korea) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Macrogen (South Korea) Main Business Overview
11.13.5 Macrogen (South Korea) Latest Developments
11.14 Geneseeq (China)
11.14.1 Geneseeq (China) Company Information
11.14.2 Geneseeq (China) Genomic Cancer Testing Product Offered
11.14.3 Geneseeq (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Geneseeq (China) Main Business Overview
11.14.5 Geneseeq (China) Latest Developments
11.15 3DMed (China)
11.15.1 3DMed (China) Company Information
11.15.2 3DMed (China) Genomic Cancer Testing Product Offered
11.15.3 3DMed (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 3DMed (China) Main Business Overview
11.15.5 3DMed (China) Latest Developments
11.16 BGI Genomics (China)
11.16.1 BGI Genomics (China) Company Information
11.16.2 BGI Genomics (China) Genomic Cancer Testing Product Offered
11.16.3 BGI Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 BGI Genomics (China) Main Business Overview
11.16.5 BGI Genomics (China) Latest Developments
11.17 Canhelp Genomics (China)
11.17.1 Canhelp Genomics (China) Company Information
11.17.2 Canhelp Genomics (China) Genomic Cancer Testing Product Offered
11.17.3 Canhelp Genomics (China) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Canhelp Genomics (China) Main Business Overview
11.17.5 Canhelp Genomics (China) Latest Developments
11.18 Lucence (Singapore)
11.18.1 Lucence (Singapore) Company Information
11.18.2 Lucence (Singapore) Genomic Cancer Testing Product Offered
11.18.3 Lucence (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Lucence (Singapore) Main Business Overview
11.18.5 Lucence (Singapore) Latest Developments
11.19 MiRXES (Singapore)
11.19.1 MiRXES (Singapore) Company Information
11.19.2 MiRXES (Singapore) Genomic Cancer Testing Product Offered
11.19.3 MiRXES (Singapore) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 MiRXES (Singapore) Main Business Overview
11.19.5 MiRXES (Singapore) Latest Developments
11.20 ACT Genomics (Taiwan)
11.20.1 ACT Genomics (Taiwan) Company Information
11.20.2 ACT Genomics (Taiwan) Genomic Cancer Testing Product Offered
11.20.3 ACT Genomics (Taiwan) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 ACT Genomics (Taiwan) Main Business Overview
11.20.5 ACT Genomics (Taiwan) Latest Developments
11.21 MedGenome (India)
11.21.1 MedGenome (India) Company Information
11.21.2 MedGenome (India) Genomic Cancer Testing Product Offered
11.21.3 MedGenome (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 MedGenome (India) Main Business Overview
11.21.5 MedGenome (India) Latest Developments
11.22 Strand Life Sciences (India)
11.22.1 Strand Life Sciences (India) Company Information
11.22.2 Strand Life Sciences (India) Genomic Cancer Testing Product Offered
11.22.3 Strand Life Sciences (India) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Strand Life Sciences (India) Main Business Overview
11.22.5 Strand Life Sciences (India) Latest Developments
11.23 Sonic Genetics (Australia)
11.23.1 Sonic Genetics (Australia) Company Information
11.23.2 Sonic Genetics (Australia) Genomic Cancer Testing Product Offered
11.23.3 Sonic Genetics (Australia) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Sonic Genetics (Australia) Main Business Overview
11.23.5 Sonic Genetics (Australia) Latest Developments
11.24 NeoGenomics (USA)
11.24.1 NeoGenomics (USA) Company Information
11.24.2 NeoGenomics (USA) Genomic Cancer Testing Product Offered
11.24.3 NeoGenomics (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 NeoGenomics (USA) Main Business Overview
11.24.5 NeoGenomics (USA) Latest Developments
11.25 Labcorp Oncology (USA)
11.25.1 Labcorp Oncology (USA) Company Information
11.25.2 Labcorp Oncology (USA) Genomic Cancer Testing Product Offered
11.25.3 Labcorp Oncology (USA) Genomic Cancer Testing Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Labcorp Oncology (USA) Main Business Overview
11.25.5 Labcorp Oncology (USA) Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Genomic Cancer Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Genomic Cancer Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Next-Generation Sequencing (NGS) Testing Products
Table 4. Major Players of Digital PCR (dPCR) Testing Products
Table 5. Major Players of Others
Table 6. Genomic Cancer Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Tissue Sample Testing
Table 10. Major Players of Blood Biopsy
Table 11. Major Players of Others
Table 12. Genomic Cancer Testing Market Size CAGR by Sample Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Genomic Cancer Testing Market Size by Sample Type (2021-2026) & ($ millions)
Table 14. Global Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2026)
Table 15. Major Players of Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
Table 16. Major Players of Genome Testing Products Specifically For Single Cancer Types
Table 17. Major Players of Others
Table 18. Genomic Cancer Testing Market Size CAGR by Cancer Type Coverage (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Genomic Cancer Testing Market Size by Cancer Type Coverage (2021-2026) & ($ millions)
Table 20. Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2026)
Table 21. Genomic Cancer Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Table 24. Global Genomic Cancer Testing Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Genomic Cancer Testing Revenue Market Share by Player (2021-2026)
Table 26. Genomic Cancer Testing Key Players Head office and Products Offered
Table 27. Genomic Cancer Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Table 32. Global Genomic Cancer Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Genomic Cancer Testing Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Genomic Cancer Testing Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Genomic Cancer Testing Market Size Market Share by Country (2021-2026)
Table 36. Americas Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Table 38. Americas Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Table 40. APAC Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Table 42. APAC Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Genomic Cancer Testing Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Genomic Cancer Testing Market Size Market Share by Country (2021-2026)
Table 46. Europe Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Genomic Cancer Testing
Table 52. Key Market Challenges & Risks of Genomic Cancer Testing
Table 53. Key Industry Trends of Genomic Cancer Testing
Table 54. Global Genomic Cancer Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Genomic Cancer Testing Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Genomic Cancer Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Genomic Cancer Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Guardant Health (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 59. Guardant Health (USA) Genomic Cancer Testing Product Offered
Table 60. Guardant Health (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Guardant Health (USA) Main Business
Table 62. Guardant Health (USA) Latest Developments
Table 63. Foundation Medicine (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 64. Foundation Medicine (USA) Genomic Cancer Testing Product Offered
Table 65. Foundation Medicine (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. Foundation Medicine (USA) Main Business
Table 67. Foundation Medicine (USA) Latest Developments
Table 68. Caris Life Sciences (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 69. Caris Life Sciences (USA) Genomic Cancer Testing Product Offered
Table 70. Caris Life Sciences (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Caris Life Sciences (USA) Main Business
Table 72. Caris Life Sciences (USA) Latest Developments
Table 73. Tempus AI (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 74. Tempus AI (USA) Genomic Cancer Testing Product Offered
Table 75. Tempus AI (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Tempus AI (USA) Main Business
Table 77. Tempus AI (USA) Latest Developments
Table 78. NeoGenomics (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 79. NeoGenomics (USA) Genomic Cancer Testing Product Offered
Table 80. NeoGenomics (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. NeoGenomics (USA) Main Business
Table 82. NeoGenomics (USA) Latest Developments
Table 83. Natera (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 84. Natera (USA) Genomic Cancer Testing Product Offered
Table 85. Natera (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Natera (USA) Main Business
Table 87. Natera (USA) Latest Developments
Table 88. OncoDNA (Belgium) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 89. OncoDNA (Belgium) Genomic Cancer Testing Product Offered
Table 90. OncoDNA (Belgium) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. OncoDNA (Belgium) Main Business
Table 92. OncoDNA (Belgium) Latest Developments
Table 93. Agendia (Netherlands) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 94. Agendia (Netherlands) Genomic Cancer Testing Product Offered
Table 95. Agendia (Netherlands) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Agendia (Netherlands) Main Business
Table 97. Agendia (Netherlands) Latest Developments
Table 98. Eurofins Clinical Diagnostics (Luxembourg) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 99. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product Offered
Table 100. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Eurofins Clinical Diagnostics (Luxembourg) Main Business
Table 102. Eurofins Clinical Diagnostics (Luxembourg) Latest Developments
Table 103. Unilabs Genetics (Switzerland) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 104. Unilabs Genetics (Switzerland) Genomic Cancer Testing Product Offered
Table 105. Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. Unilabs Genetics (Switzerland) Main Business
Table 107. Unilabs Genetics (Switzerland) Latest Developments
Table 108. Nucleix (Israel) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 109. Nucleix (Israel) Genomic Cancer Testing Product Offered
Table 110. Nucleix (Israel) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Nucleix (Israel) Main Business
Table 112. Nucleix (Israel) Latest Developments
Table 113. Genetron Health (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 114. Genetron Health (China) Genomic Cancer Testing Product Offered
Table 115. Genetron Health (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. Genetron Health (China) Main Business
Table 117. Genetron Health (China) Latest Developments
Table 118. Macrogen (South Korea) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 119. Macrogen (South Korea) Genomic Cancer Testing Product Offered
Table 120. Macrogen (South Korea) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. Macrogen (South Korea) Main Business
Table 122. Macrogen (South Korea) Latest Developments
Table 123. Geneseeq (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 124. Geneseeq (China) Genomic Cancer Testing Product Offered
Table 125. Geneseeq (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. Geneseeq (China) Main Business
Table 127. Geneseeq (China) Latest Developments
Table 128. 3DMed (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 129. 3DMed (China) Genomic Cancer Testing Product Offered
Table 130. 3DMed (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. 3DMed (China) Main Business
Table 132. 3DMed (China) Latest Developments
Table 133. BGI Genomics (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 134. BGI Genomics (China) Genomic Cancer Testing Product Offered
Table 135. BGI Genomics (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. BGI Genomics (China) Main Business
Table 137. BGI Genomics (China) Latest Developments
Table 138. Canhelp Genomics (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 139. Canhelp Genomics (China) Genomic Cancer Testing Product Offered
Table 140. Canhelp Genomics (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Canhelp Genomics (China) Main Business
Table 142. Canhelp Genomics (China) Latest Developments
Table 143. Lucence (Singapore) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 144. Lucence (Singapore) Genomic Cancer Testing Product Offered
Table 145. Lucence (Singapore) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Lucence (Singapore) Main Business
Table 147. Lucence (Singapore) Latest Developments
Table 148. MiRXES (Singapore) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 149. MiRXES (Singapore) Genomic Cancer Testing Product Offered
Table 150. MiRXES (Singapore) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 151. MiRXES (Singapore) Main Business
Table 152. MiRXES (Singapore) Latest Developments
Table 153. ACT Genomics (Taiwan) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 154. ACT Genomics (Taiwan) Genomic Cancer Testing Product Offered
Table 155. ACT Genomics (Taiwan) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 156. ACT Genomics (Taiwan) Main Business
Table 157. ACT Genomics (Taiwan) Latest Developments
Table 158. MedGenome (India) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 159. MedGenome (India) Genomic Cancer Testing Product Offered
Table 160. MedGenome (India) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 161. MedGenome (India) Main Business
Table 162. MedGenome (India) Latest Developments
Table 163. Strand Life Sciences (India) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 164. Strand Life Sciences (India) Genomic Cancer Testing Product Offered
Table 165. Strand Life Sciences (India) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 166. Strand Life Sciences (India) Main Business
Table 167. Strand Life Sciences (India) Latest Developments
Table 168. Sonic Genetics (Australia) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 169. Sonic Genetics (Australia) Genomic Cancer Testing Product Offered
Table 170. Sonic Genetics (Australia) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 171. Sonic Genetics (Australia) Main Business
Table 172. Sonic Genetics (Australia) Latest Developments
Table 173. NeoGenomics (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 174. NeoGenomics (USA) Genomic Cancer Testing Product Offered
Table 175. NeoGenomics (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 176. NeoGenomics (USA) Main Business
Table 177. NeoGenomics (USA) Latest Developments
Table 178. Labcorp Oncology (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 179. Labcorp Oncology (USA) Genomic Cancer Testing Product Offered
Table 180. Labcorp Oncology (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 181. Labcorp Oncology (USA) Main Business
Table 182. Labcorp Oncology (USA) Latest Developments
Table 1. Genomic Cancer Testing Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Genomic Cancer Testing Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Next-Generation Sequencing (NGS) Testing Products
Table 4. Major Players of Digital PCR (dPCR) Testing Products
Table 5. Major Players of Others
Table 6. Genomic Cancer Testing Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 7. Global Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 8. Global Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Table 9. Major Players of Tissue Sample Testing
Table 10. Major Players of Blood Biopsy
Table 11. Major Players of Others
Table 12. Genomic Cancer Testing Market Size CAGR by Sample Type (2021 VS 2025 VS 2032) & ($ millions)
Table 13. Global Genomic Cancer Testing Market Size by Sample Type (2021-2026) & ($ millions)
Table 14. Global Genomic Cancer Testing Market Size Market Share by Sample Type (2021-2026)
Table 15. Major Players of Broad-Spectrum Genomic Testing Products For Pan-Solid Tumors
Table 16. Major Players of Genome Testing Products Specifically For Single Cancer Types
Table 17. Major Players of Others
Table 18. Genomic Cancer Testing Market Size CAGR by Cancer Type Coverage (2021 VS 2025 VS 2032) & ($ millions)
Table 19. Global Genomic Cancer Testing Market Size by Cancer Type Coverage (2021-2026) & ($ millions)
Table 20. Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage (2021-2026)
Table 21. Genomic Cancer Testing Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 22. Global Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 23. Global Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Table 24. Global Genomic Cancer Testing Revenue by Player (2021-2026) & ($ millions)
Table 25. Global Genomic Cancer Testing Revenue Market Share by Player (2021-2026)
Table 26. Genomic Cancer Testing Key Players Head office and Products Offered
Table 27. Genomic Cancer Testing Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 28. New Products and Potential Entrants
Table 29. Mergers & Acquisitions, Expansion
Table 30. Global Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 31. Global Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Table 32. Global Genomic Cancer Testing Revenue by Country/Region (2021-2026) & ($ millions)
Table 33. Global Genomic Cancer Testing Revenue Market Share by Country/Region (2021-2026)
Table 34. Americas Genomic Cancer Testing Market Size by Country (2021-2026) & ($ millions)
Table 35. Americas Genomic Cancer Testing Market Size Market Share by Country (2021-2026)
Table 36. Americas Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 37. Americas Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Table 38. Americas Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 39. Americas Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Table 40. APAC Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 41. APAC Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Table 42. APAC Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 43. APAC Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 44. Europe Genomic Cancer Testing Market Size by Country (2021-2026) & ($ millions)
Table 45. Europe Genomic Cancer Testing Market Size Market Share by Country (2021-2026)
Table 46. Europe Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 47. Europe Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 48. Middle East & Africa Genomic Cancer Testing Market Size by Region (2021-2026) & ($ millions)
Table 49. Middle East & Africa Genomic Cancer Testing Market Size by Type (2021-2026) & ($ millions)
Table 50. Middle East & Africa Genomic Cancer Testing Market Size by Application (2021-2026) & ($ millions)
Table 51. Key Market Drivers & Growth Opportunities of Genomic Cancer Testing
Table 52. Key Market Challenges & Risks of Genomic Cancer Testing
Table 53. Key Industry Trends of Genomic Cancer Testing
Table 54. Global Genomic Cancer Testing Market Size Forecast by Region (2027-2032) & ($ millions)
Table 55. Global Genomic Cancer Testing Market Size Market Share Forecast by Region (2027-2032)
Table 56. Global Genomic Cancer Testing Market Size Forecast by Type (2027-2032) & ($ millions)
Table 57. Global Genomic Cancer Testing Market Size Forecast by Application (2027-2032) & ($ millions)
Table 58. Guardant Health (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 59. Guardant Health (USA) Genomic Cancer Testing Product Offered
Table 60. Guardant Health (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 61. Guardant Health (USA) Main Business
Table 62. Guardant Health (USA) Latest Developments
Table 63. Foundation Medicine (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 64. Foundation Medicine (USA) Genomic Cancer Testing Product Offered
Table 65. Foundation Medicine (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 66. Foundation Medicine (USA) Main Business
Table 67. Foundation Medicine (USA) Latest Developments
Table 68. Caris Life Sciences (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 69. Caris Life Sciences (USA) Genomic Cancer Testing Product Offered
Table 70. Caris Life Sciences (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 71. Caris Life Sciences (USA) Main Business
Table 72. Caris Life Sciences (USA) Latest Developments
Table 73. Tempus AI (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 74. Tempus AI (USA) Genomic Cancer Testing Product Offered
Table 75. Tempus AI (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 76. Tempus AI (USA) Main Business
Table 77. Tempus AI (USA) Latest Developments
Table 78. NeoGenomics (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 79. NeoGenomics (USA) Genomic Cancer Testing Product Offered
Table 80. NeoGenomics (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 81. NeoGenomics (USA) Main Business
Table 82. NeoGenomics (USA) Latest Developments
Table 83. Natera (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 84. Natera (USA) Genomic Cancer Testing Product Offered
Table 85. Natera (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 86. Natera (USA) Main Business
Table 87. Natera (USA) Latest Developments
Table 88. OncoDNA (Belgium) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 89. OncoDNA (Belgium) Genomic Cancer Testing Product Offered
Table 90. OncoDNA (Belgium) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 91. OncoDNA (Belgium) Main Business
Table 92. OncoDNA (Belgium) Latest Developments
Table 93. Agendia (Netherlands) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 94. Agendia (Netherlands) Genomic Cancer Testing Product Offered
Table 95. Agendia (Netherlands) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 96. Agendia (Netherlands) Main Business
Table 97. Agendia (Netherlands) Latest Developments
Table 98. Eurofins Clinical Diagnostics (Luxembourg) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 99. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Product Offered
Table 100. Eurofins Clinical Diagnostics (Luxembourg) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 101. Eurofins Clinical Diagnostics (Luxembourg) Main Business
Table 102. Eurofins Clinical Diagnostics (Luxembourg) Latest Developments
Table 103. Unilabs Genetics (Switzerland) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 104. Unilabs Genetics (Switzerland) Genomic Cancer Testing Product Offered
Table 105. Unilabs Genetics (Switzerland) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 106. Unilabs Genetics (Switzerland) Main Business
Table 107. Unilabs Genetics (Switzerland) Latest Developments
Table 108. Nucleix (Israel) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 109. Nucleix (Israel) Genomic Cancer Testing Product Offered
Table 110. Nucleix (Israel) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 111. Nucleix (Israel) Main Business
Table 112. Nucleix (Israel) Latest Developments
Table 113. Genetron Health (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 114. Genetron Health (China) Genomic Cancer Testing Product Offered
Table 115. Genetron Health (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 116. Genetron Health (China) Main Business
Table 117. Genetron Health (China) Latest Developments
Table 118. Macrogen (South Korea) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 119. Macrogen (South Korea) Genomic Cancer Testing Product Offered
Table 120. Macrogen (South Korea) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 121. Macrogen (South Korea) Main Business
Table 122. Macrogen (South Korea) Latest Developments
Table 123. Geneseeq (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 124. Geneseeq (China) Genomic Cancer Testing Product Offered
Table 125. Geneseeq (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 126. Geneseeq (China) Main Business
Table 127. Geneseeq (China) Latest Developments
Table 128. 3DMed (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 129. 3DMed (China) Genomic Cancer Testing Product Offered
Table 130. 3DMed (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 131. 3DMed (China) Main Business
Table 132. 3DMed (China) Latest Developments
Table 133. BGI Genomics (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 134. BGI Genomics (China) Genomic Cancer Testing Product Offered
Table 135. BGI Genomics (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 136. BGI Genomics (China) Main Business
Table 137. BGI Genomics (China) Latest Developments
Table 138. Canhelp Genomics (China) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 139. Canhelp Genomics (China) Genomic Cancer Testing Product Offered
Table 140. Canhelp Genomics (China) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 141. Canhelp Genomics (China) Main Business
Table 142. Canhelp Genomics (China) Latest Developments
Table 143. Lucence (Singapore) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 144. Lucence (Singapore) Genomic Cancer Testing Product Offered
Table 145. Lucence (Singapore) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 146. Lucence (Singapore) Main Business
Table 147. Lucence (Singapore) Latest Developments
Table 148. MiRXES (Singapore) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 149. MiRXES (Singapore) Genomic Cancer Testing Product Offered
Table 150. MiRXES (Singapore) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 151. MiRXES (Singapore) Main Business
Table 152. MiRXES (Singapore) Latest Developments
Table 153. ACT Genomics (Taiwan) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 154. ACT Genomics (Taiwan) Genomic Cancer Testing Product Offered
Table 155. ACT Genomics (Taiwan) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 156. ACT Genomics (Taiwan) Main Business
Table 157. ACT Genomics (Taiwan) Latest Developments
Table 158. MedGenome (India) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 159. MedGenome (India) Genomic Cancer Testing Product Offered
Table 160. MedGenome (India) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 161. MedGenome (India) Main Business
Table 162. MedGenome (India) Latest Developments
Table 163. Strand Life Sciences (India) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 164. Strand Life Sciences (India) Genomic Cancer Testing Product Offered
Table 165. Strand Life Sciences (India) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 166. Strand Life Sciences (India) Main Business
Table 167. Strand Life Sciences (India) Latest Developments
Table 168. Sonic Genetics (Australia) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 169. Sonic Genetics (Australia) Genomic Cancer Testing Product Offered
Table 170. Sonic Genetics (Australia) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 171. Sonic Genetics (Australia) Main Business
Table 172. Sonic Genetics (Australia) Latest Developments
Table 173. NeoGenomics (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 174. NeoGenomics (USA) Genomic Cancer Testing Product Offered
Table 175. NeoGenomics (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 176. NeoGenomics (USA) Main Business
Table 177. NeoGenomics (USA) Latest Developments
Table 178. Labcorp Oncology (USA) Details, Company Type, Genomic Cancer Testing Area Served and Its Competitors
Table 179. Labcorp Oncology (USA) Genomic Cancer Testing Product Offered
Table 180. Labcorp Oncology (USA) Genomic Cancer Testing Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 181. Labcorp Oncology (USA) Main Business
Table 182. Labcorp Oncology (USA) Latest Developments
LIST OF FIGURES
Figure 1. Genomic Cancer Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Genomic Cancer Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Genomic Cancer Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Genomic Cancer Testing Sales Market Share by Country/Region (2025)
Figure 8. Genomic Cancer Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Genomic Cancer Testing Market Size Market Share by Type in 2025
Figure 10. Global Genomic Cancer Testing Market Size Market Share by Sample Type in 2025
Figure 11. Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage in 2025
Figure 12. Genomic Cancer Testing in Healthcare Institutions
Figure 13. Global Genomic Cancer Testing Market: Healthcare Institutions (2021-2026) & ($ millions)
Figure 14. Genomic Cancer Testing in Biopharmaceuticals and Pharmaceuticals
Figure 15. Global Genomic Cancer Testing Market: Biopharmaceuticals and Pharmaceuticals (2021-2026) & ($ millions)
Figure 16. Genomic Cancer Testing in Independent Medical Laboratories
Figure 17. Global Genomic Cancer Testing Market: Independent Medical Laboratories (2021-2026) & ($ millions)
Figure 18. Genomic Cancer Testing in Others
Figure 19. Global Genomic Cancer Testing Market: Others (2021-2026) & ($ millions)
Figure 20. Global Genomic Cancer Testing Market Size Market Share by Application in 2025
Figure 21. Global Genomic Cancer Testing Revenue Market Share by Player in 2025
Figure 22. Global Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Figure 23. Americas Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 24. APAC Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 25. Europe Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 27. Americas Genomic Cancer Testing Value Market Share by Country in 2025
Figure 28. United States Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Genomic Cancer Testing Market Size Market Share by Region in 2025
Figure 33. APAC Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 34. APAC Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 35. China Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. India Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Genomic Cancer Testing Market Size Market Share by Country in 2025
Figure 42. Europe Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 43. Europe Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 44. Germany Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. France Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 58. APAC Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 59. Europe Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 61. United States Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 62. Canada Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 63. Mexico Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 64. Brazil Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 65. China Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 66. Japan Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 67. Korea Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 69. India Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 70. Australia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 71. Germany Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 72. France Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 73. UK Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 74. Italy Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 75. Russia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 76. Egypt Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 77. South Africa Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 78. Israel Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 79. Turkey Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 80. Global Genomic Cancer Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Genomic Cancer Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 1. Genomic Cancer Testing Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Genomic Cancer Testing Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Genomic Cancer Testing Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Genomic Cancer Testing Sales Market Share by Country/Region (2025)
Figure 8. Genomic Cancer Testing Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Genomic Cancer Testing Market Size Market Share by Type in 2025
Figure 10. Global Genomic Cancer Testing Market Size Market Share by Sample Type in 2025
Figure 11. Global Genomic Cancer Testing Market Size Market Share by Cancer Type Coverage in 2025
Figure 12. Genomic Cancer Testing in Healthcare Institutions
Figure 13. Global Genomic Cancer Testing Market: Healthcare Institutions (2021-2026) & ($ millions)
Figure 14. Genomic Cancer Testing in Biopharmaceuticals and Pharmaceuticals
Figure 15. Global Genomic Cancer Testing Market: Biopharmaceuticals and Pharmaceuticals (2021-2026) & ($ millions)
Figure 16. Genomic Cancer Testing in Independent Medical Laboratories
Figure 17. Global Genomic Cancer Testing Market: Independent Medical Laboratories (2021-2026) & ($ millions)
Figure 18. Genomic Cancer Testing in Others
Figure 19. Global Genomic Cancer Testing Market: Others (2021-2026) & ($ millions)
Figure 20. Global Genomic Cancer Testing Market Size Market Share by Application in 2025
Figure 21. Global Genomic Cancer Testing Revenue Market Share by Player in 2025
Figure 22. Global Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Figure 23. Americas Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 24. APAC Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 25. Europe Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 26. Middle East & Africa Genomic Cancer Testing Market Size 2021-2026 ($ millions)
Figure 27. Americas Genomic Cancer Testing Value Market Share by Country in 2025
Figure 28. United States Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 29. Canada Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 30. Mexico Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 31. Brazil Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 32. APAC Genomic Cancer Testing Market Size Market Share by Region in 2025
Figure 33. APAC Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 34. APAC Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 35. China Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 36. Japan Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 37. South Korea Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 38. Southeast Asia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 39. India Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 40. Australia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 41. Europe Genomic Cancer Testing Market Size Market Share by Country in 2025
Figure 42. Europe Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 43. Europe Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 44. Germany Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 45. France Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 46. UK Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 47. Italy Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 48. Russia Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 49. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Region (2021-2026)
Figure 50. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Type (2021-2026)
Figure 51. Middle East & Africa Genomic Cancer Testing Market Size Market Share by Application (2021-2026)
Figure 52. Egypt Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 53. South Africa Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 54. Israel Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 55. Turkey Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 56. GCC Countries Genomic Cancer Testing Market Size Growth 2021-2026 ($ millions)
Figure 57. Americas Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 58. APAC Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 59. Europe Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 60. Middle East & Africa Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 61. United States Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 62. Canada Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 63. Mexico Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 64. Brazil Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 65. China Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 66. Japan Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 67. Korea Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 68. Southeast Asia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 69. India Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 70. Australia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 71. Germany Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 72. France Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 73. UK Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 74. Italy Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 75. Russia Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 76. Egypt Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 77. South Africa Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 78. Israel Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 79. Turkey Genomic Cancer Testing Market Size 2027-2032 ($ millions)
Figure 80. Global Genomic Cancer Testing Market Size Market Share Forecast by Type (2027-2032)
Figure 81. Global Genomic Cancer Testing Market Size Market Share Forecast by Application (2027-2032)
Figure 82. GCC Countries Genomic Cancer Testing Market Size 2027-2032 ($ millions)
